Plus: Creator Fund closes €48.6M fund, Joyvié Health raises €897k for continence underwear, and AMH testing trends.
Thena Capital, an all-female GP firm, raised £45m for its debut healthcare fund, providing new capital opportunities for early-stage femtech operators and founders in Europe and the US. Concurrently, Creator Fund closed its €48.6 million fund with KfW Capital as its largest investor, signaling continued interest in early-stage European life sciences, including fertility innovations. These funding rounds for new and existing funds focus investment activity in digital health, AI, and biotech for femtech stakeholders. Five takes inside, plus a quick-hits roundup.
Thena Capital raised £45m for its debut healthcare fund. The all-female GP firm plans to invest in 12-15 Seed to Series A stage digital health and AI companies across Europe and the US, including those focused on women’s health and fertility. This funding provides new capital opportunities for femtech operators and founders in early stages.
Read the full story →Creator Fund closed its first European fund at €48.8 million ($56 million) with KfW Capital as its largest investor. The fund has made 11 investments to date, including Ovo Labs, a biotech company focused on reversing the aging of human eggs. This funding signals continued investor interest in early-stage European life sciences, including fertility innovations relevant to femtech operators.
Read the full story →Joyvié Health closed a £771K pre-seed round, with funding from Innovate UK, HERmesa Angels, SyndicateRoom, and Lavender Ventures. The UK-based company will develop patent-pending reusable continence underwear that contains stool in a disposable pouch immediately after excretion. This funding supports innovation in fecal incontinence solutions for femtech operators.
Read the full story →Joyvié Health closed a €897k pre-Seed funding round. The funding, including an Innovate UK grant and investments from HERmesa Angels, SyndicateRoom, and Lavender Ventures, will support a direct-to-consumer product launch and clinical pilots. Joyvié's continence underwear demonstrated a 90% reduction in stool-to-skin contact and 70% faster changes in early testing, addressing faecal incontinence affecting 656 million people globally, disproportionately women. This funding for a women-founded startup in women's health impacts investors seeking opportunities in underserved markets.
Read the full story →AMH testing has become one of the most-requested blood tests in private women’s health in the UK and has gone mainstream over the past few years. However, AMH only indicates egg quantity, not quality, and fertility test results do not guarantee fertility outcomes. For femtech operators, clinicians, and consumers, this highlights the need for careful interpretation of AMH results, specifically when paired with age, imaging, and other markers by a clinician, especially given that no UK clinical body recommends AMH as a routine screening test for healthy women without fertility concerns.
Read the full story →